



PHYTOTECH MEDICAL

ASX RELEASE

2 February 2015

CHANGE OF COMPANY SECRETARY AND REGISTERED OFFICE

PhytoTech Medical Limited (ASX:PYL), the Australian owned Medical Grade Cannabis (MGC) company and the first MGC company to list on the Australian Stock Exchange, wishes to advise that Miss Eryln Dale has been appointed company secretary of the Company, effective from 1 February 2015.

Miss Dale has a broad range of experience in corporate governance and company compliance having been involved with several ASX listed companies. Miss Dale holds a Bachelor of Commerce (Accounting and Finance) and is currently completing further governance qualifications.

Simultaneous to the appointment of Miss Dale is the resignation of Miss Loren Jones as company secretary of the Company. The Company wishes to thank Miss Jones for her contribution to the Company.

PhytoTech Medical Limited ACN: 601 236 417
Physical: Suite 25, 145 Stirling Highway, Nedlands WA 6009
Postal: P.O. Box 3144, Nedlands WA 6009
Ph: (08) 9389 3150 Web: www.phytotechmed.com

For personal use only



ASX RELEASE CONTINUED

The Company's registered office and principal place of business will move to:

Physical address: Suite 25, 145 Stirling Highway, Nedlands WA 6009

Phone number: +61 (0) 8 9389 3150

Postal address: PO Box 3144, Nedlands WA 6009

The change to the new Company address and phone number is effective from 1 February 2015.

-Ends-

For more information please contact

Boaz Wachtel, Managing Director

+61 8 9389 3150

info@phytotechmed.com

For media enquiries

Media & Capital Partners

Asher Moses, Associate Director

+61 438 008 616

Asher.moses@mcpartners.com.au



About PhytoTech Medical Limited

PhytoTech Medical is a medical cannabis company, which aims to commercialise Medical Grade Cannabis (MGC) and high potential cannabis based therapeutics products to the rapidly growing international market with regulated medical cannabis laws. With research facilities located in Israel, a global leader in medical cannabis research, the Company is strategically positioned to become a key player in the global MGC market.

The Company is focused on the research, development and commercialisation of products for administering MGC, and on new treatments utilising MGC therapeutic components for various medical conditions. In addition, the Company aims to grow proprietary strains of MGC in California, Uruguay and other jurisdictions.

PhytoTech has entered into an exclusive research and licensing agreement with Yissum, the prestigious Research Development and technology transfer Company of Hebrew University in Jerusalem, Israel. Yissum was founded in 1964 to protect and to commercialise the Hebrew University's intellectual property. Products based on Hebrew University technologies that have been commercialised by Yissum currently generate US\$2 Billion in annual sales. Ranked among the top technology transfer companies in the world, Yissum has registered over 8,500 patents covering 2,400 inventions; has licensed out 750 technologies and has spun out 90 companies. Yissum's partners span



ASX RELEASE CONTINUED

the globe and include names such as Microsoft, Johnson & Johnson, Syngenta, Monsanto, Roche, Novartis, Merck, Teva and many more.

Using proprietary technology, PhytoTech's vision is to administer ground breaking health benefits of cannabinoids in oral preparations, vapor form, and other routes of administration in safe and effective ways.

<http://www.phytotechmed.com/>

For personal use only